COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

• DOI: 10.1007/s15010-020-01438-z
• Publication Date: 2020-05-11T07:02:51Z
• Authors: Georg Härter; Christoph D. Spinner; Julia Roider; Markus Bickel; Ivanka Krznaric; Stephan Grunwald; Farhad Schabaz; Daniel Gillor; Nils Postel; Matthias C. Mueller; Markus Müller; Katja Römer; Knud Schewe; Christian Hoffmann
• Keywords: Darunavir; Regimen; Pandemic; Protease inhibitor (pharmacology)

Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients COVID-19 reveals symptoms and outcome this special population.Retrospective analysis anonymized data including age, gender, HIV-associated parameters, symptoms, outcome.Three out 32 documented outcomes died (9%). 91% recovered 76% have been classified as mild cases. All were antiretroviral treatment, them 22 tenofovir-containing regimen 4 protease inhibitor darunavir.This preliminary does not support excess morbidity mortality among symptomatic viral suppression ART. infections may occur during boosted darunavir-based and/or